Myelofibrosis Clinical Trial Tracker — Stay Current on JAK Inhibitor Combinations and Novel Mechanisms

Why myelofibrosis trial monitoring matters

Myelofibrosis (MF) is a rare but life-threatening myeloproliferative neoplasm with a median survival of 5–7 years in intermediate-2 and high-risk patients. Despite its relatively small patient population — approximately 20,000 prevalent cases in the United States — myelofibrosis is one of the most commercially significant rare blood cancers due to the high value of each patient treated and the unmet need for disease-modifying therapy beyond symptom control.

The JAK inhibitor approvals of ruxolitinib, fedratinib, pacritinib, and momelotinib created a competitive class but left substantial unmet need: spleen volume response, symptom control, and survival improvement remain only partial with monotherapy. The result is an explosion of combination trial activity, with dozens of programs pairing approved JAK inhibitors with agents targeting complementary biology. Key signals to track:

• JAK inhibitor + novel agent combination trials — BET inhibitors, BCL2/BCL-XL, PI3K delta, MDM2, and LSD1 inhibitors
• Navitoclax (BCL-XL/BCL2) combinations with ruxolitinib — Phase 3 program outcomes and competitors
• Pelabresib (CPI-0610, BET inhibitor) combinations — pivotal trial readouts and next-generation BET programs
• Imetelstat (telomerase inhibitor) — a distinct mechanism targeting the clonal stem cell
• Allogeneic stem cell transplant conditioning and post-transplant protocols
• Mutation-specific programs: JAK2 V617F-targeted, CALR-mutant, and MPL-mutant approaches
• Anemia-focused trials — momelotinib's ACVR1/ALK2 mechanism and competitors addressing transfusion dependence

What we monitor for myelofibrosis

Our pipeline pulls directly from the ClinicalTrials.gov API every day. For a myelofibrosis watch profile, you can configure:

• Condition keywords: "myelofibrosis", "primary myelofibrosis", "post-polycythemia vera myelofibrosis", "post-essential thrombocythemia myelofibrosis", "myeloproliferative neoplasm", "JAK2 V617F"
• Phase filter: Phase 1 only, Phase 2/3, or all phases
• Sponsor filter: Industry-sponsored only (for competitive intelligence) or all sponsors
• Status filter: Recruiting only, all active studies, or any status

The myelofibrosis treatment landscape in 2026

JAK inhibitors: the established backbone

Four JAK inhibitors are now approved in myelofibrosis, each with a distinct clinical profile. Ruxolitinib (Jakafi, Incyte/Novartis) remains the dominant first-line agent, with robust spleen and symptom data and a decade of real-world experience. Fedratinib (Inrebic, Bristol Myers Squibb) provides an option after ruxolitinib failure with activity in accelerated phase disease. Pacritinib (Vonjo, CTI BioPharma/Swedish Orphan Biovitrum) targets patients with severe thrombocytopenia (platelets <50,000). Momelotinib (Ojjaara, GSK) differentiates through ACVR1 inhibition, which addresses hepcidin-mediated anemia and reduces transfusion dependence — the only approved agent with both spleen/symptom and anemia labeling.

Despite this class expansion, JAK inhibitor monotherapy produces only modest rates of complete or partial cytogenetic remission, and disease progression eventually occurs in most patients. This creates the rationale for combination development.

BET inhibitor combinations: pelabresib and the epigenetic approach

Pelabresib (CPI-0610, Constellation Pharmaceuticals/MorphoSys/Novartis) inhibits BET bromodomain proteins — transcriptional regulators that control oncogenic gene expression in MF stem cells. The MANIFEST-2 Phase 3 trial evaluated pelabresib + ruxolitinib as frontline combination therapy and reported superior spleen volume response and symptom reduction compared to ruxolitinib alone. This represents a potentially paradigm-shifting result in first-line MF. Monitoring trial registrations for pelabresib and competitor BET inhibitor programs captures what may be the next wave of MF treatment intensification.

BCL2/BCL-XL inhibition: navitoclax combinations

Navitoclax, a dual BCL-XL/BCL2 inhibitor developed by AbbVie, has demonstrated spleen and bone marrow fibrosis responses in combination with ruxolitinib in Phase 2. The TRANSFORM-1 Phase 3 trial registered navitoclax + ruxolitinib as a frontline combination. Thrombocytopenia remains the primary dose-limiting toxicity of navitoclax, and next-generation BCL-XL selective inhibitors with improved platelet safety profiles are entering clinical development — creating a dynamic competitive space worth monitoring.

MDM2 inhibition: targeting the p53 pathway

MDM2 inhibitors activate the p53 tumor suppressor pathway and have shown activity in JAK2-mutant myeloproliferative neoplasms. KRT-232 (karuna) and other MDM2 inhibitors have demonstrated splenic responses and reduction in mutant allele burden in early trials. Combination studies with JAK inhibitors are registering, and the approach has particular appeal in TP53 wild-type MF where p53 activation may drive clonal suppression.

Imetelstat: a telomerase inhibitor with distinct biology

Imetelstat (Rytelo, Geron) inhibits telomerase, the enzyme that maintains telomere length in malignant progenitor cells. Approved in lower-risk myelodysplastic syndromes, imetelstat has shown response rates including complete remissions in heavily pretreated MF patients in the IMbark trial. Its mechanism of targeting the disease-propagating stem cell, rather than downstream signaling, positions it distinctly from JAK inhibitors and makes it a candidate for combination or sequencing approaches.

Mutation-specific biology: JAK2, CALR, and MPL

Approximately 95% of MF patients carry a driver mutation in JAK2 (V617F, ~60%), CALR (~25%), or MPL (~8%). These mutations have distinct biology, prognosis, and potentially distinct drug sensitivity. CALR-mutant MF has a better prognosis overall but different response kinetics to JAK inhibitors. CAR-T and bispecific antibody programs targeting CALR-mutant cells are entering Phase 1 trials, representing a genuinely mutation-specific cellular approach that warrants monitoring.

Stem cell transplant: the only curative option

Allogeneic hematopoietic stem cell transplant remains the only potentially curative treatment in myelofibrosis. Clinical trials investigating conditioning intensity, graft-versus-host disease prophylaxis strategies, post-transplant maintenance with JAK inhibitors, and optimal patient selection continue to register. Academic transplant centers are active in this space, and monitoring these trials is important for transplant programs and companies developing post-transplant maintenance agents.

Who uses myelofibrosis trial monitoring

Hematology oncologists and academic medical centers

Myelofibrosis is concentrated at academic medical centers and specialized hematology practices with MPN programs. Physicians at these centers monitor trial registrations to identify enrollment opportunities for their patients, track emerging combinations before publication, and prepare for changes to treatment guidelines as pivotal trial data mature.

Specialized hematology investors

Investors with positions in Incyte, Novartis, Bristol Myers Squibb, AbbVie, GSK, and emerging MF biotechs track trial activity to assess pipeline depth, competitive positioning, and potential for combination-driven market expansion. In rare disease oncology, trial registrations are often the first public indication of a company's clinical strategy for multi-year development programs.

Biopharma business development teams

The combination development wave in MF has created significant licensing and partnering activity. BD teams track Phase 1 and Phase 2 trial registrations for novel agents being developed by smaller companies — identifying potential combination partners or acquisition targets before clinical data mature and valuations increase.

Frequently asked questions

How current is the myelofibrosis trial data?

Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest.

Can I track combination trials separately from monotherapy trials?

Yes. On the Pro plan ($149/month), you can create multiple search profiles. You might have one profile for JAK inhibitor combinations, another for CALR-mutant specific programs, and another for transplant protocols — each delivering a focused daily digest.

Does this cover the broader MPN landscape including polycythemia vera and essential thrombocythemia?

Yes. You can add "polycythemia vera", "essential thrombocythemia", or "myeloproliferative neoplasm" as condition keywords in your search profile to capture the broader MPN trial landscape alongside myelofibrosis-specific studies.

How is this different from ClinicalTrials.gov alerts?

ClinicalTrials.gov offers basic RSS-style alerts without phase filtering, sponsor type filtering, or organized digest formatting. We provide filtered, labeled, and organized alerts — the intelligence layer on top of the raw registry data.

Can I filter for specific mutation types like JAK2 V617F or CALR?

Yes. Including specific mutation identifiers as keywords alongside condition terms lets you narrow your digest to mutation-specific programs or biomarker-selected trials most relevant to your interests.